Evidence map›Paper›PMID 34741199›Full record

ReviewCurrent diabetes reports2021

Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes.

David D Berg, Ahmed A Kolkailah, Ashish Sarraju, Anne Marie Kerchberger, Mahmoud Eljalby, Darren K McGuire

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus.Journal of the American College of Cardiology · 2023 · on this map
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

David D BergTIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Suite 7022, Boston, MA, 02115, USA. dberg1@bwh.harvard.edu.
Ahmed A KolkailahUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID https://orcid.org/0000-0002-3327-1718
Ashish SarrajuDivision of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Anne Marie KerchbergerUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID https://orcid.org/0000-0003-3596-7169
Mahmoud EljalbyUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
Darren K McGuireUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-6412-7989
Parkland Health & Hospital System · USBrigham and Women's Hospital · USCardiovascular Institute of the South · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) have increased the focus of type 2 diabetes mellitus (T2DM) care on comprehensive cardiovascular risk reduction. Herein, we review the results of the cardiovascular outcomes trials of SGLT2i and GLP-1 RA, discuss the concepts of relative vs. absolute risk reduction in the context of these trials, and highlight the importance of individualized risk assessment when applying trial results to clinical practice. RECENT

findingsTo enable personalized treatment approaches, multiple clinical risk scores have been developed to assess risk of atherosclerotic cardiovascular disease (ASCVD) outcomes and hospitalization for heart failure (HHF) in patients with T2DM. In addition, circulating biomarkers of myocardial injury (cardiac troponin) and hemodynamic stress (natriuretic peptides) have been shown to further refine risk prediction of these clinically important cardiovascular complications. When making decisions about whether to initiate SGLT2i and GLP-1 RA, clinicians should consider the anticipated relative and absolute treatment benefits from these antihyperglycemic therapies. Clinicians can use available clinical and biomarker-based risk tools when counseling patients about their individual cardiovascular risk profiles and when estimating absolute treatment benefits from SGLT2i and GLP-1 RA.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsRisk AssessmentGlucagon-Like Peptide-1 ReceptorHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsAtherosclerotic cardiovascular diseaseCardiovascular riskGlucagon-like peptide 1 receptor agonistHeart failureSodium-glucose cotransporter-2 inhibitorType 2 diabetes mellitus

Identifiers

PMID34741199
OpenAlexW3210825702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.